However, PAC-1 inhibition by the higher dose PGI2 was diminished in the type 1 diabetes group compared with control participants following stimulation with 10 μg/ml CRP-XL (reduction of 79 ± 18% vs 94 ± 3%, p=0.01) and the SFLLRN/CRP-XL combination at both inhibitor doses (3 ± 14% vs 16 ± 7%, p=0.007 at 10 nmol/l PGI2 and 47 ± 29% vs 84 ± 8%, p<0.001 at 100 nmol/l PGI2; Fig. 3h). The gene discussed is CRP; the disease is type 1 diabetes mellitus.